Lexaria Bioscience Corp.
LEXX · XNASCIK 1348362fmd_0HAD0QWYQPQE04EB2K1QGQ4Y59Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Aug 01, 2009 to May 31, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net interest income | – | – | – | – | – | – | – | 0 | 0 | – |
| Gross profit | (0) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | – | 0 |
| Research and development | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 4 | 2 | 8 |
| Non-interest income | – | – | – | – | – | – | 0 | 0 | – | – |
| Total operating expenses | 1 | 2 | 7 | 4 | 4 | 6 | 7 | 7 | 6 | 13 |
| Compensation and benefits | – | – | – | 0 | 0 | – | – | – | – | – |
| Operating income | (1) | (2) | (7) | (4) | (4) | (6) | (7) | (7) | (6) | (12) |
| Interest expense | 0 | 0 | – | – | – | – | – | 0 | 0 | – |
| Other non-operating income (expense) | – | – | – | – | – | – | (1) | (0) | (0) | (0) |
| Income before taxes | (1) | (2) | (7) | (4) | (4) | (4) | (7) | (7) | (6) | (12) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Net income from continuing operations | (1) | (2) | (7) | (4) | (4) | (4) | (7) | – | – | – |
| Net income | (1) | (2) | 7 | 4 | (4) | (4) | (7) | (7) | (6) | (12) |
| Net income to common shareholders | (1) | (2) | (7) | (4) | (4) | (4) | (7) | – | – | – |